ON

BeOne Medicines Ltd.

ONC · Nasdaq

BeOne Medicines Ltd. (ONC) is a Medical pharmaceuticals company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for BeOne Medicines Ltd. in 2026. The next earnings report is expected on August 27, 2026.

Scheduled earnings dates

27 Aug 2026 05 Nov 2026

Earnings calendar

Next earnings date

27 Aug 2026

In 6 days

EPS estimate

1.53

Revenue estimate

1.6B

Past earnings

05 Aug 2026
EPS actual
3.84 (+99.2%)
estimate 1.93
Revenue actual
1.7B (+4.3%)
estimate 1.6B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
—
estimate 1.20
Revenue actual
—
estimate 1.5B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 May 2026
EPS actual
1.96 (+27.5%)
estimate 1.54
Revenue actual
1.5B (+2.5%)
estimate 1.5B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
26 Feb 2026
EPS actual
0.60 (-51.8%)
estimate 1.24
Revenue actual
1.5B (+2.2%)
estimate 1.5B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Nov 2025
EPS actual
1.09 (+28.1%)
estimate 0.85
Revenue actual
1.4B (+3.4%)
estimate 1.4B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

BeOne Medicines Ltd. beat consensus estimates in its latest earnings report, with EPS of usd 3.84 coming in 99.2% above expectations and revenue of usd 1.71 billion exceeding estimates by 4.3%. Both EPS and revenue were also ahead of expectations in the previous report.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

Sector
Healthcare
Industry
Medical pharmaceuticals
Country
United States
Exchange
Nasdaq
CEO
John V. Oyler
Employees
11,000
IPO date
02 Feb 2016
ISIN
US07725L1026
Website
beonemedicines.com

Frequently asked questions

When does BeOne Medicines Ltd. (ONC) next report earnings?

BeOne Medicines Ltd. (ONC) is scheduled to report earnings on August 27, 2026.

What was BeOne Medicines Ltd.'s most recent earnings date?

BeOne Medicines Ltd. (ONC) last reported earnings on August 5, 2026.

Where is BeOne Medicines Ltd. stock listed?

BeOne Medicines Ltd. (ONC) is listed on Nasdaq.